X4 Pharmaceuticals Inc
XFOR5.335USD
+5.145+2707.89%
收盘 04/28, 16:00（美东）报价延迟15分钟
912.00M总市值
亏损市盈率 TTM
关于 X4 Pharmaceuticals Inc 公司
X4 Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发用于治疗罕见疾病和治疗选择有限的疾病的新型疗法，重点是治疗由免疫系统功能障碍引起的疾病。其主要临床候选药物是 mavorixafor，一种趋化因子受体 CXCR4 的小分子选择性拮抗剂，正在开发为口服、每日一次的疗法。该公司已经开发了一系列趋化因子受体 CXC 受体 4 型 (CXCR4) 的小分子口服拮抗剂。该公司有两种临床前候选药物：X4P-003，一种第二代 CXCR4 拮抗剂，旨在具有比 mavorixafor 更强的特性，可能为 CXCR4 依赖性疾病和原发性免疫缺陷提供机会，以及 X4P-002，一种具有分布特征和已证实能够穿过血脑屏障的 CXCR4 拮抗剂。
公司简介
公司代码XFOR
公司名称X4 Pharmaceuticals Inc
上市日期Nov 16, 2017
成立日期2010
CEODr. Paula Ragan, Ph.D.
员工数量143
证券类型Ordinary Share
年结日Nov 16
公司地址61 North Beacon Street
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02134
电话18575298300
网址https://www.x4pharma.com/
公司代码XFOR
上市日期Nov 16, 2017
成立日期2010
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
Mr. David W.J. Mcgirr
Mr. David W.J. Mcgirr
Independent Director
Independent Director
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Ms. Francoise De Craecker
Ms. Francoise De Craecker
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 2月23日 周日
更新时间: 2月23日 周日
持股股东
股东类型
持股股东
股东统计
占比
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
持股股东
股东统计
占比
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
股东类型
股东统计
占比
Investment Advisor
25.05%
Investment Advisor/Hedge Fund
11.85%
Venture Capital
8.63%
Hedge Fund
5.73%
Private Equity
4.92%
Individual Investor
2.32%
Research Firm
1.96%
Bank and Trust
0.09%
Pension Fund
0.04%
Other
39.41%
机构持股
更新时间: 3月5日 周三
更新时间: 3月5日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q1
216
105.29M
60.63%
-54.29M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
2023Q3
189
132.64M
89.63%
+450.20K
2023Q2
191
133.25M
115.52%
+52.30M
2023Q1
171
81.27M
73.10%
+5.35M
2022Q4
172
79.41M
72.57%
+27.33M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bain Capital Life Sciences Investors, LLC
16.92M
9.74%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
14.99M
8.63%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
10.26M
5.91%
-93.42K
-0.90%
Dec 31, 2024
The Vanguard Group, Inc.
8.20M
4.72%
-239.83K
-2.84%
Dec 31, 2024
Acorn Capital Advisors, LLC
7.31M
4.21%
--
--
Dec 31, 2024
OrbiMed Advisors, LLC
7.13M
4.11%
--
--
Dec 31, 2024
Kingdon Capital Management, L.L.C.
4.94M
2.84%
+298.32K
+6.43%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.50M
2.01%
+49.70K
+1.44%
Dec 31, 2024
AXA Investment Managers UK Ltd.
3.07M
1.77%
-4.80K
-0.16%
Dec 31, 2024
State Street Global Advisors (US)
3.06M
1.76%
+104.40K
+3.54%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Simplify Propel Opportunities ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
ProShares UltraPro Russell2000
占比0%
iShares Russell 2000 Value ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Proshares Ultra Russell 2000
占比0%
Simplify Propel Opportunities ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Global X Russell 2000 ETF
占比0%
iShares Russell 2000 ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据